

● Posters List

CLINICAL TRIALS – PHASE IIB & III	P.2
CLINICAL TRIALS – PHASE I & IIA	P.3
NON-PHARMACOLOGIC INTERVENTIONS	P.4
IMAGING (MRI & PET)	P.5
BIOMARKERS (CSF & PLASMA)	P.7
ARTIFICIAL INTELLIGENCE-DRIVEN INNOVATION IN ALZHEIMER'S THERAPEUTICS	P.11
EPIDEMIOLOGY	P.12
PRE-CLINICAL, EARLY DISCOVERY AND MECHANISTIC RESEARCH	P.13
TRIAL DESIGN, STATISTICAL INNOVATION, AND ANALYTICAL FRAMEWORKS	P.15
COGNITIVE AND FUNCTIONAL OUTCOMES	P.17
DIGITAL ENDPOINTS, REMOTE MONITORING, AND CONNECTED HEALTH TOOLS	P.19
NEW HYPOTHESES – NEW THERAPEUTIC APPROACHES FOR AD	P.20

CLINICAL TRIALS – PHASE IIB & III

P33 Evolution of Late-Stage Alzheimer's Disease Clinical Trial Design: Toward Biomarker-Driven, Precision Development

Presenter: Laurentiu Gutiu

Laurentiu GUTIU ¹, Abby FULLER ², Todorova ANTONIYA ³

¹ Fortrea Germany GmbH, Munich, Germany, ² Fortrea Inc., Durham, United-States, ³ Fortrea Belgium SRL, Brussels, Belgium

P148 Evaluation of Sex and APOE4-Related Differences in Baseline Characteristics and Disease Progression Among Placebo-Treated Patients in Anti-Amyloid Alzheimer's Clinical Trials

Presenter: Kevin Krudys

Athanasios CHAMZAS, Gopichand GOTTIPATI, Ananth Ram NOOKALA, Venkatesh Atul BHATTARAM, Mehul MEHTA, Ramana UPPOOR, Kevin KRUDYS, Sreedharan SABARINATH

Center for Drug Evaluation and Research, FDA, Silver Spring, United-States

P161 Masupirdine (a pure 5-HT6 receptor antagonist): Baseline demographic and clinical characteristics of the phase-3 clinical study targeting agitation in patients with dementia of Alzheimer's type

Presenter: Ramakrishna Nirogi

Ramakrishna NIROGI, Satish JETTA, Vinod Kumar GOYAL, Vijay BENADE, Anil SHINDE, Santosh Kumar PANDEY, Ramkumar SUBRAMANIAN, Abdul Rasheed MOHAMMED, Dhanunjay DOGIPARTI, Pradeep JAYARAJAN, Venkat JASTI

Suven Life Sciences Ltd, Hyderabad, India

P294 Standardizing the Unstandardized: Common SAPS H+D Rater Errors in Dementia Trials and a Training Framework to Close the Gap

Presenter: Sayaka Machizawa

Sayaka MACHIZAWA ¹, Erica APPLEMAN ¹, Amanda Mandy AEDO ¹, Gila BARBATI ¹, Alicia CAPECE ¹, Joan DEGEORGE ¹, Andrei IACOB ²

¹ Signant Health, Blue Bell, United-States, ² Signant Health, Iasi, Romania

P511 Oral Blarcamesine Clinical Effect In a Phase 2b/3 Early AD Population For SIGMAR1 And Col24a1 Genotypes

Presenter: Marwan Sabbagh

Marwan SABBAGH ¹, Audrey GABELLE ², Timo GRIMMER ³, Juan-Carlos TALAVERA ⁴, Jeffrey EDWARDS ⁴, Terrie KELLMEYER ⁴

¹ Barrow Neurological Institute, Phoenix, United-States, ² University of Montpellier, Montpellier, France, ³ Technical University of Munich, Munich, Germany, ⁴ Anavex, New York, United-States

P550 C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 programme at Neuroclnx Glasgow.

Presenter: Kanwal Aadil

Kanwal AADIL, Lewis COWAN, Jennifer LYNCH, Fraser INGLIS

Neuroclnx Glasgow, Motherwell, United Kingdom

CLINICAL TRIALS – PHASE I & IIA

P29 Global Exploratory Phase 2 Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of TML-6, a Synthetic Curcumin Analog Targeting the Autolysosomal Pathway in Early Alzheimer's Disease: Study Design and Rationale

Presenter: Hiep Nguyen

Ih Jen SU^{1,2}, Chien-Hong LIN², Chia-Yu HSU², Hui-Chen WANG², Hiep NGUYEN³, Feng-Shiun SHIE⁴

¹ Department of Biotechnology and Food Technology, Southern Taiwan University of Science and Technology, Tainan City, Taiwan, ² Merry Life Biomedical Company, Tainan City, Taiwan, ³ Nguyen Scientific, Encinitas, United-States, ⁴ Center for Neuropsychiatric Research National Health Research Institutes, Zhunan Town, Taiwan

P84 Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): Update on progress in a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate

Presenter: Linda Van Eldik

Linda VAN ELDIK¹, Wendy ZIAI², Lauren SANSING³, D. Martin WATTERSON⁴, Saktimayee ROY⁴, Daniel HANLEY²

¹ University of Kentucky, Lexington, United-States, ² Johns Hopkins Univ, Baltimore, United-States, ³ Yale University, New Haven, United-States, ⁴ Northwestern University, Chicago, United-States

P171 THN391 – A First-In-Class Anti-fibrin Antibody for Treatment of Inflammation in Alzheimer's Disease: Update of an Ongoing Phase 1b Study for the Treatment of Early Alzheimer's Disease

Presenter: Nuno Mendonca

Nuno MENDONCA¹, Aaron B. KANTOR¹, Tanja A.M. HOFFMAN¹, Sarah KAVANAGH¹, Henk J.M.M. MUTSAERTS², Frederik BARKHOF², Khalid ABD-ELAZIZ³, E. Jort G.B. VIJVERBERG², Catherine MUMMERY⁴, Craig RITCHIE⁵

¹ Therini Bio, Sacramento, Ca, United-States, ² Amsterdam UMC, Amsterdam, The Netherlands, ³ CTC Groningen, Groningen, The Netherlands, ⁴ University College London Hospitals, London, United Kingdom, ⁵ Scottish Brain Sciences, Edinburgh, United Kingdom

P224 First-in-Human Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator, in Healthy Human Subjects

Presenter: Anil Shinde

Anil SHINDE, Vinod Kumar GOYAL, Veera Raghava Chowdary PALACHARLA, Ramkumar SUBRAMANIAN, Satish JETTA, Pradeep JAYARAJAN, Vijay BENADE, Santosh Kumar PANDEY, Dhanunjay DOGIPARTI, Ilayaraja KALAIKADHIBAN, Abdul Rasheed MOHAMMED, Ramakrishna NIROGI, Venkat JASTI

Suven Life Sciences, Hyderabad, India

P291 Operational Strategies for Executing Complex Multi-Arm Phase 1 Alzheimer's Disease Clinical Trials

Presenter: Liza Moore

Liza MOORE

Clinilabs, Eatontown, United-States

P417 Phase 1b Proof-of-Mechanism Trial of EC5026, a Soluble Epoxide Hydrolase Inhibitor, in Biomarker-Confirmed Early Alzheimer's Disease

Presenter: Myuri Ruthirakuhan

Myuri RUTHIRAKUHAN¹, Cindy MCREYNOLDS², William SCHMIDT², Heather HSU², Mario MASELLIS¹, Sandra BLACK¹, Walter SWARDFAGER¹

¹ Sunnybrook Research Institute, Toronto, On, Canada, ² EicOsis Human Health Inc., Davis, Ca, United-States

NON-PHARMACOLOGIC INTERVENTIONS

P101 Impact of a Multidomain Lifestyle Intervention on Gut Microbiota: An Exploratory Sub-study of the SUPERBRAIN Trial

Presenter: Seong Hye Choi

Seong Hye CHOI¹, Jee Hyang JEONG², Yangki MINN³, Woorim KANG⁴, So Young MOON⁵, Yoo Kyoung PARK⁶

¹ Inha University College of Medicine, Incheon, Republic of Korea, ² Ewha Womans University School of Medicine, Seoul, Republic of Korea, ³ Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea, ⁴ Kangwon National University, Chuncheon, Republic of Korea, ⁵ Ajou University School of Medicine, Suwon, Republic of Korea, ⁶ Graduate School of East-West Medical Nutrition, Kyung Hee University, Yongin, Republic of Korea

P134 Nutritional Status and Cognitive Function: Role of Apolipoprotein E α 4 in the Elderly

Presenter: Shin Gyeom Kim

Young Min CHOI¹, Shin Gyeom KIM², Jee Wook KIM¹

¹ Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea, ² Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea

P393 Differential Cognitive Responses to Active and Sham rTMS Combined with Cognitive Training in Early Alzheimer's Disease

Presenter: Juyoun Lee

Juyoun LEE¹, Inho LEE², Kun Ho KIM³, Ae Young LEE¹

¹ Department of Neurology, School of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea, ² Department of Radiology, School of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea, ³ Department of Nuclear Medicine, School of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea

P500 Neural substrates generating a gamma frequency response to 40Hz GENUS light and sound stimulation

Presenter: Diane Chan

Diane CHAN^{1,2}, Ute GEIGENMULLER¹, Monica ZHENG¹, Andrew BECKER¹, Erika RUIZ¹, Remi PHILIPS¹, Natalie HAHN¹, Aaron BOES^{3,4}, Matthew HOWARD^{3,4}, Eleonora MARCANTONI⁵, Simon HANSLMAYR⁵, Diego VIDAURRE HENCHE^{6,7,8}, Emery BROWN^{1,9}, Edward BOYDEN¹, Li-Huei TSAI¹

¹ MIT, Cambridge, United-States, ² Alnylam, Cambridge, United-States, ³ University of Iowa, Iowa City, United-States, ⁴ Iowa Neuroscience Institute, Iowa City, United-States, ⁵ Centre for Neurotechnology, Glasgow, United Kingdom, ⁶ Centre de Recerca Matemàtica, Barcelona, Espagne, ⁷ University of Oxford, Oxford, United Kingdom, ⁸ Aarhus University, Aarhus, Denmark, ⁹ Massachusetts General Hospital, Boston, United-States

P563 Augmented Exercise Interventions: Optimizing Response to Exercise Modalities for Cognitive Enhancement in Early AD

Presenter: Krista Lanctot

Krista LANCTOT¹, Julian SCHECTER¹, Yejin KANG¹, Sandra BLACK¹, Nathan HERRMANN², Sara MITCHELL¹, Susan MARZOLINI³, Paul OH³, Jennifer RABIN¹, Tarek RAJJI⁴, Mark RAPOPORT¹, Walter SWARDFAGER¹, Mehreen SIDDIQUI¹, Kate SURVILLA¹, Damien GALLAGHER¹

¹ Sunnybrook Research Institute, Toronto, Canada, ² Department of Psychiatry, University of Toronto, Toronto, Canada, ³ KITE Research Institute, Toronto Rehabilitation Institute – University Health Network, Toronto, Canada, ⁴ Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, United-States

IMAGING (MRI & PET)

P40 The Pronghorn Sign: Hunting for a Radiologic Biomarker in LBD

Presenter: Preston Roche

Preston ROCHE ¹, Samy ABDULLAH ¹, James RINI ², Leila SAADATPOUR ^{1,3}, Alicia PARKER ^{1,3}

¹ UT San Antonio, San Antonio, United-States, ² OCHSNER Health, New Orleans, United-States, ³ Biggs Institute

P61 Tau PET signature of amyloid PET visual-positive/quantitative-negative discordance despite low global amyloid burden in ADNI

Presenter: Saki Nakashima

Saki NAKASHIMA ¹, Kenichiro SATO ², Yoshiki NIIMI ², Wataru SATAKE ¹, Takeshi IWATSUBO ³

¹ Department of Neurology, Graduate School of Medicine, The University of Tokyo - Tokyo Japan, Tokyo, Japon, ² Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japon, ³ National Center of Neurology and Psychiatry, Tokyo, Japon

P73 Predictors of ARIA-H in A4 Study: White matter hyperintensity and APOE ϵ 4 selectively influence lobar microhemorrhages

Presenter: Zahra Shirzadi

Zahra SHIRZADI ¹, Nazila LOGHMANI ², Aaron SCHULTZ ¹, Wai-Ying YAU ¹, Hyun-Sik YANG ¹, Roy YAARI ³, Michael PROPERZI ¹, Michael S. RAFII ⁴, Clifford R. JACK JR ⁵, Steven M. GREENBERG ¹, Paul AISEN ⁴, Reisa A. SPERLING ¹, Jasmeer P. CHHATWAL ¹

¹ Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, United-States, ² Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, United-States, ³ Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United-States, ⁴ Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United-States, ⁵ Mayo Clinic, Radiology, Rochester, United-States

P92 Predictors of longitudinal amyloid clearance due to lecanemab treatment: A preliminary report from a real-world clinical cohort

Presenter: Yuta Katsumi

Yuta KATSUMI ¹, Neguine REZAI ¹, Kirk DAFFNER ², John DICKSON ¹, Jeremy FORD ¹, Seth GALE ², Teresa GOMEZ-ISLA ¹, Gad MARSHALL ², Liliana RAMIREZ GOMEZ ¹, Dennis SELKOE ², Hyun-Sik YANG ², Wai-Ying YAU ¹, Mark ELDAIEF ¹, Scott MCGINNIS ², Bradford DICKERSON ¹

¹ Massachusetts General Hospital, Boston, United-States, ² Brigham and Women's Hospital, Boston, United-States

P191 Retinal layer thickness predicts cerebral amyloid burden in preclinical Alzheimer's disease

Presenter: Jordan Sergio

Jordan SERGIO ^{1,2,3}, Cyrus RAJI ⁴, Ashley BERNARDO ^{1,2}, Megan STRADTMAN ⁵, Savannah A. DOSTER ^{2,3}, Rachel LACROIX ^{3,5}, Emma T. LARRACEY ^{2,3}, Mahshid NAGHASHZADEH ⁴, Mobina AMANOLLAHI ⁴, Soheil MOHAMMADI ⁴, Mona MIRBEYK ⁴, Mahsa DOLATSHAHI ⁴, Peter SNYDER ^{1,2,6}, Jessica ALBER ^{1,2,3,6}

¹ Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, United-States, ² Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, United-States, ³ Butler Hospital Memory & Aging Program, Providence, United-States, ⁴ Neuroimaging Labs Research Center at Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, United-States, ⁵ Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, United-States, ⁶ George & Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, United-States

P219 Advanced Arterial Compliance Impairment Is Associated with Tau Accumulation and Progressive Neurodegeneration

Presenter: Young Noh

Young NOH ¹, Jaelim CHO ², Yeo Jin KIM ³, Ha-Eun SEO ⁴, Daegyeom KIM ⁴, Jihyun BAE ⁴, Sang-Yoon LEE ⁵, Kee Hyung PARK ⁶, Geert Jan BIESELS ⁷, Jae-Hong LEE ⁸, Keun-Hwa JUNG ⁹

¹ Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ² Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea,

³ Department of Neurology, Kangdong Sacred Heart Hospital, Seoul, Republic of Korea, ⁴ Neuroscience Research Institute, Gachon University, Incheon, Republic of Korea, ⁵ Department of Neuroscience, College of

Medicine, Gachon University, Incheon, Republic of Korea, ⁶ Department of Neurology, Gachon University Gil Medical Center, Incheon, Republic of Korea, ⁷ Department of Neurology, UMC Utrecht, Utrecht, The Netherlands,

⁸ Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, ⁹ Department of Neurology, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea

P286 Distinct Associations Between Hippocampal Subfield Volumes and Episodic Memory in Alzheimer's Disease

Presenter: Giulia Tronchin

Giulia TRONCHIN, Mintao LIU, Tina WANG, Alette Maria WESSELS, Ming LU, Vikas KOTARI, Sergey SHCHERBININ

Eli Lilly and Company, Indianapolis, United-States

P304 Therapeutic Amyloid Reduction and Cortical Excitability in Alzheimer's Disease (TRACE-AD) Study Protocol and Early-Stage Findings.

Presenter: Basma Goma

Basma GOMAA ^{1,2}, Stephanie BUSS ^{1,2}

¹ Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Boston, United-States, ² Department of Neurology, Harvard Medical School, Boston, United-States

P320 Evaluation of atrophy-defined subtypes in early symptomatic Alzheimer's disease

Presenter: Vikas Kotari

Mintao LIU, Vikas KOTARI, Jiaying GUO, Adam S. FLEISHER, Rik OSSENKOPPELE, Sergey SHCHERBININ

Eli Lilly and Company, United-States

P323 MRI-based enrichment for pathology-targeted progressive supranuclear palsy trials in non-fluent variant primary progressive aphasia

Presenter: Jesús García-Castro

Jesús GARCÍA-CASTRO ¹, Maria Luisa MANDELLI ², Alexandre BEJANIN ¹, Oriol DOLS-ICARDO ¹, Juan FORTEA ¹, Daniel ALCOLEA ¹, Alberto LLEÓ ¹, Kejal KANTARCI ³, Hilary W. HEUER ², Howard ROSEN ², Brad BOEVE ³, Adam BOXER ², Zachary MILLER ², Maria Luisa GORNO-TEMPINI ², Ignacio ILLÁN-GALA ¹

¹ Hospital de la Santa Creu i Sant Pau, Barcelona, Espagne, ² Memory and Aging Center, UCSF, San Francisco, United-States, ³ Mayo Clinic, Rochester, United-States

P467 Longitudinal evolution of enlarged perivascular spaces across the AD continuum

Presenter: Luc Bracoud

Luc BRACOUD ¹, Alessandro DELMONTE ¹, Thomas CAJGFINGER ¹, Madhura INGALHALIKAR ², Chris CONKLIN ², Joel SCHAEERER ³, Meredith BURKE ², David SCOTT ²

¹ Clario, part of Thermo Fisher Scientific, Lyon, France, ² Clario, part of Thermo Fisher Scientific, Philadelphia, United-States, ³ Clario, part of Thermo Fisher Scientific, Geneva, Suisse

P472 Comparison of test-retest variability and longitudinal stability of total intracranial volume measurement between atlas-based and segmentation-based MRI methods

Presenter: Luc Bracoud

Thomas CAJGFINGER ¹, Alessandro DELMONTE ¹, Madhura INGALHALIKAR ², Chris CONKLIN ², Joel SCHAEERER ³, Meredith BURKE ⁴, David SCOTT ⁴, Luc BRACOUD ¹

¹ Clario, part of Thermo Fisher Scientific, Lyon, France, ² Clario, part of Thermo Fisher Scientific, Philadelphia, Îles mineures éloignées des United-States, ³ Clario, part of Thermo Fisher Scientific, Geneva, Suisse, ⁴ Clario, part of Thermo Fisher Scientific, Philadelphia, United-States

P554 Contribution of the automated MRI segmentation of the brain trophicity in the diagnosis of Lewy Body Disease in a clinical center

Presenter: Claire Paquet

Christine DELMAIRE ¹, Julien SAVATOVSKY ², Claire HOURREGUE ³, Esteban MUNOZ ³, Emmanuel MORAIN ³, Fabien HAUW ³, Agathe VRILLON ³, Claire PAQUET ³

¹ Fondation Rothschild, Radiology, Paris, France, ² Fondation Rothschild, Radiology - Paris France, Paris, France, ³ Hôpital Fernand Widal, Assistance Publique Hôpitaux de Paris, Centre de Neurologie Cognitive - Paris France, Paris, France

P678 Portable, Low-field MRI Combined with Machine Learning Segmentation for Cognitively Impaired Individuals

Presenter: Ava Farnan

Ava FARNAN ^{1,2}, Annabel J. SORBY-ADAMS ^{1,2}, John R. DICKSON ¹, Liliana RAMIREZ GOMEZ ¹, Arman FESHARAKI-ZADEH ³, Christopher VAN DYCK ⁴, Matthew S. ROSEN ⁵, Kevin N. SHETH ⁴, J. Eugenio IGLESIAS ⁶, Adam DE HAVENON ⁴, Teresa GOMEZ-ISLA ¹, Alberto SERRANO POZO ¹, W. Taylor KIMBERLY ^{7,2}

¹ Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, United-States, ² Center for Genomic Medicine, Massachusetts General Hospital, Boston, United-States,

³ Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA, New Haven, United-States, ⁴ Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA - United States, New Haven, United-States, ⁵ Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA - United States, Boston, United-States, ⁶ Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, United-States, ⁷ Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA - United States, Boston, United-States

BIOMARKERS (CSF & PLASMA)

P13 Baseline Biomarker Profiles in the Diverse Vascular Contributions to Cognitive Impairment and Dementia (DVCID) Study

Presenter: Sitong (agnes) Zhou

Sitong Agnes ZHOU¹, Jacopo DI LUCENTE¹, Jacob CONSTON¹, Danielle HARVEY¹, Myriam FORNAGE², Charles DECARLI¹, Lee-Way JIN¹
¹ University of California, Davis, Sacramento, United-States, ² UTHealth Houston School of Public Health, Houston, United-States

P23 Temporal and Dose-Dependent Modulation of the Endocannabinoid System by Dual FAAH/MAGL Inhibition in Humans: Implications for Alzheimer's Disease

Presenter: Jie Li

Jie LI¹, Sumit BANSAL², Rui ZHAO², Joel SCHWARTZ², Rosa MICELI², Marc GLEICHMANN², Yongjun XUE², Mary COFFEY², Yi LUO², Sarah HARRIS²

¹ BMS, San Diego, United-States, ² BMS, Princeton, United-States

P71 Reducing the P-tau217 Diagnostic Grey Zone Through Multimarker and Sequential Strategies Incorporating Plasma A β in Mild Cognitive Impairment

Presenter: María Pascual-Lucas

María PASCUAL-LUCAS¹, Leticia SARASA¹, Noelia FANDOS¹, Jorge LOSCOS¹, Judith ROMERO¹, Adrián SÁNCHEZ¹, Jose TERCENIO^{2,1}, Isabel ORTEGA-MADUEÑO³, María Cruz CÁRDENAS³, Fernando CAVA-VALENCIANO³, María José GIL-MORENO⁴, Jordi A MATÍAS-GUIU⁴, Jose Antonio ALLUÉ¹

¹ Araclon Biotech-Grifols, Zaragoza, Espagne, ² Grifols, Barcelona, Espagne, ³ Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Espagne, ⁴ Department of Neurology, Hospital Clínico San Carlos, Madrid, Espagne

P116 Using Digital Twins to Improve Statistical Efficiency in Alzheimer's Disease Trials with p-tau217

Presenter: Anoop Praturu

Anoop PRATURU, Coco KUSIAK
Unlearn AI, San Francisco, United-States

P120 Real-World Adoption of Blood Biomarkers to Support Timely Diagnosis of Alzheimer's Disease: Ongoing Multinational Implementation Study

Presenter: Amy Deckert

Monica ZIGMAN SUCHSLAND, Karen WEYRAUCH, Tim MACLEOD, Katherine J. SELZLER, Alissa KURZMAN, Amy DECKERT
Davos Alzheimer's Collaborative, Wayne, United-States

P127 Estimating the durability of residual effects on biomarkers after discontinuation of lecanemab

Presenter: Jie Janice Pan

Simon ROTHWELL¹, Jie Janice PAN², Daniela ROSSI¹, Jo VANDERCAPPELLEN³, Cianne PARK⁴, Indiag SLY⁴
¹ Eisai Europe LTD, Hatfield, United Kingdom, ² Eisai Inc, Nutley, New Jersey, United-States, ³ Eisai Pharma AG, Zurich, Suisse, ⁴ Acumetis, London, United Kingdom

P132 Association of HDL Cholesterol With Longitudinal Brain Tau Deposition: A Cross-Ethnic Cohort Study

Presenter: Jee Wook Kim

Jee Wook KIM¹, Hye Ji I CHO¹, Shin Gyeom KIM², Dong Young LEE³
¹ Hallim University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea, ² Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea, ³ Seoul National University Hospital, Seoul, Republic of Korea

P147 Optimization of a Rapid, Cost-Effective qPCR Assay for Apolipoprotein E Genotyping

Presenter: Lauren Johnson

Lauren JOHNSON¹, Sarah AUGUSTE MCCAULLEY¹, Isabelle PHILIPP¹, Zuguang WANG¹, Matthew STICCO², Logan VERO², Kavita JAIN², Ganesan ANTHONY², Arejas UZGIRIS¹

¹ Siemens Healthcare Diagnostics, East Walpole, United-States, ² Siemens Healthcare Diagnostics, Tarrytown, United-States

P157 Healthcare Provider Perspectives and Confidence in Using Alzheimer's Blood Biomarkers in Clinical Practice

Presenter: Amy Deckert

Monica ZIGMAN SUCHSLAND, Karen WEYRAUCH, Katherine SELZLER, Tim MACLEOD, Alissa KURZMAN, Amy DECKERT
Davos Alzheimer's Collaborative, Wayne, United-States

P163 Prediction of Amyloid Positivity Using Historical EMR-Derived CBC and Chemistry Data

Presenter: Amir Glik

Amir GLIK ^{1,2,3,4}, Boaz CITRIN ^{1,2}, Marianna ABAJYAN ^{1,2}, Hayim RACLAW ^{1,2}, Gal AVIRAM ^{1,2}

¹ ALZAI Health Corp., Toronto, Canada, ² ALZAI Health Israel Ltd, Givatayim, Israël, ³ Cognitive Neurology Clinic, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israël, ⁴ 2Faculty of Medicine, Tel Aviv University, Tel Aviv, Israël

P196 Real-World Plasma Neurofilament Light Chain, Functional Staging Severity, and Amyloid PET Non-Concordance in an Underrepresented Multimorbid Gulf/MENA Memory-Clinic Cohort

Presenter: Hanan Sheikh Ibrahim,md,facp

Hanan SHEIKH IBRAHIM,MD,FACP

Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates ² Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA, Abu Dhabi, Émirats Arabes Unis

P236 Factors influencing longitudinal plasma phospho-tau 217 and 181 changes in Alzheimer's dementia – a memory clinic follow-up study.

Presenter: Michaela Defrancesco

Michaela DEFRADESCO, Christian HUMPEL

Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria, Innsbruck, Austria

P251 Amyloid Pathology Modulates the Proteomic Architecture of Global Cognition

Presenter: Sokratis Charisis

Vasiliki Amaryllis SKYFA ^{1,2}, Christopher PAPANDREOU ¹, Martina SAMIOTAKI ³, Georgios HADJIGEORGIOU ⁴, Efthimios DARDIOTIS ⁵, Mary H. KOSMIDIS ⁶, Mary YANNAKOULIA ⁷, Paraskevi SAKKA ⁸, Archontoula DROUKA ⁷, Dora BRIKOU ⁷, Eirini MAMALAKI ⁷, Eva NTANASI ², Nikolaos SCARMEAS ², Sokratis CHARISIS ⁹, Athos ANTONIADES ¹⁰

¹ Department of Nutrition and Dietetics, School of Health Sciences, Hellenic Mediterranean University, Crete, Grèce, ² First Department of Neurology, Aiginion Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Grèce, ³ Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Grèce, ⁴ Department of Neurology, Medical School, University of Cyprus, Nicosia, Chypre, ⁵ Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Grèce, ⁶ Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Grèce, ⁷ Department of Nutrition and Dietetics, Harokopio University, Athens, Grèce, ⁸ Athens Association of Alzheimer's Disease and Related Disorders, Athens, Grèce, ⁹ Harvard Medical School & Massachusetts General Hospital, Boston, United-States, ¹⁰ Stremble Ventures LTD, Limassol, Chypre

P254 Domain-Specific CSF Proteomic Signatures of Cognitive Function in the ALBION Cohort

Presenter: Sokratis Charisis

Vasiliki Amaryllis SKYFA ^{1,2}, Christopher PAPANDREOU ¹, Martina SAMIOTAKI ³, Georgios HADJIGEORGIOU ⁴, Efthimios DARDIOTIS ⁵, Mary H. KOSMIDIS ⁶, Mary YANNAKOULIA ⁷, Paraskevi SAKKA ⁸, Archontoula DROUKA ⁷, Dora BRIKOU ⁷, Eirini MAMALAKI ⁷, Eva NTANASI ², Nikolaos SCARMEAS ², Sokratis CHARISIS ⁹, George MANIAS ¹⁰

¹ Department of Nutrition and Dietetics, School of Health Sciences, Hellenic Mediterranean University, Crete, Grèce, ² First Department of Neurology, Aiginion Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Grèce, ³ Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Grèce, ⁴ Department of Neurology, Medical School, University of Cyprus, Nicosia, Chypre, ⁵ Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Grèce, ⁶ Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Grèce, ⁷ Department of Nutrition and Dietetics, Harokopio University, Athens, Grèce, ⁸ Athens Association of Alzheimer's Disease and Related Disorders, Athens, Grèce, ⁹ Harvard Medical School & Massachusetts General Hospital, Boston, United-States, ¹⁰ Department of Digital Systems, University of Piraeus, Piraeus, Grèce

P256 Development and Analytical Validation of a Plasma ELISA for Glial Fibrillary Acidic Protein (GFAP) and Exploratory Analysis in a Clinical Cohort of Patients with Alzheimer's disease

Presenter: Noelia Fandos

Noelia FANDOS ¹, Raquel RODRÍGUEZ ¹, Judith ROMERO ¹, María PASCUAL-LUCAS ¹, José Antonio ALLUÉ ¹, Leticia SARASA ¹, Jesús CANUDAS ¹, Ignacio MARTÍNEZ ¹, María MONTAÑÉS ¹, Jose TERENCIO ^{2,1}, Jorge LOSCOS ¹

¹ Araclon Biotech, Zaragoza, Espagne, ² Grifols, Sant Cugat Del Vallès, Barcelona, Espagne

P311 Circular RNA Blood-Based Biomarkers Reliably Predict Progression of Asymptomatic Individuals to Alzheimer's Disease: ADRC and A4/LEARN Cohort Replication

Presenter: Jessica Dehart

Bridget PHILLIPS ¹, Jessie SANFORD ¹, Vaibhav JANVE ², Nikolaos MELLIOS ³, Grigorios PAPAGEORGIOU ³, Jessica DEHART ³, John MORRIS ¹, Joel PERLMUTTER ¹, Paul KOTZBAUER ¹, Richard PERRIN ¹, Timothy HOHMAN ², Laura IBANEZ ¹, Carlos CRUCHAGA ¹

¹ Washington University School of Medicine, St. Louis, United-States, ² Vanderbilt University Medical Center, Nashville, United-States, ³ Circular Genomics, San Diego, United-States

P489 Improved Stratification of Parkinson's Disease Using a Novel Ratio Analysis of Total and pS129-?-Synuclein Enabled by the SPEAR Platform

Presenter: Tracy Liu

Jeremy TAN, Emma TORDOFF, Erden EREN, Tucker FONTANA, Tsz Wing FAN, Tracy LIU, Xue FENG
Spear Bio, Woburn, United-States

P498 Distribution of Biomarkers Among Patients Meeting Clinical Criteria for Alzheimer's Disease Psychosis Who Are Biomarker Negative for Amyloid Proteinopathy and p-Tau217

Presenter: Samantha Friend

Samantha FRIEND ¹, Bryan DIRKS ², Becky HOWELL ², Xiaoshu FENG ², Sanjeev PATHAK ²
¹ Acadia Pharmaceuticals Inc., San Diego, United-States, ² Acadia Pharmaceuticals Inc., Princeton, United-States

P506 A Novel 5-Plex SPEAR Assay Targeting BD-pTau 217, eMTBR-Tau, BD-Tau, NF-L and GFAP Enables Comprehensive Assessment of Alzheimer's Disease Pathology and Neurodegeneration

Presenter: Tracy Liu

Ahsan AUSAF ALI, Jiachong CHU, Pengyu HAO, Xi CHEN, Arian PUSHKA, Chi TANG, Zidong WANG, Tracy LIU, Feng XUAN
Spear Bio, Woburn, United-States

P589 Analytical Validation of a novel liquid chromatography–tandem mass spectrometry (LC-MS/MS) multiplexed method measuring three phosphorylated forms of tau protein in plasma for Research Use.

Presenter: Venky Venkatesh

Matthew MEYER, Xinping LIU, Faith IRVIN, Mark ADAMS, Tim WEST, Venky VENKATESH, John BUI, Justine COPPINGER, Philip VERGHESE
C2N Diganostics, LLC, Saint Louis, United-States

P656 Establishing a Biobank Registry for Limbic-predominant Age-related TDP-43 Encephalopathy at Sutter Health

Presenter: Shawn Kile

Shawn KILE, Armen MOUGHAMIAN, Kimberly CHRISTENSEN, Tammy DONNEL, Sarah ROBINSON, Katherine GILLESPIE, Gregory TRANAH
Sutter Health Research Institute, San Francisco, United-States

P719 Astroglial Activation and Neurodegeneration as Kinetic Switches for p-Tau 217 Progression: A Longitudinal Multi-Analyte Stratification Analysis

Presenter: David Wilson

David WILSON, Lindsey METTE, Meenakshi KHARE, Matt POLACK, Jorge MARQUES
Quanterix, Billerica, United-States

ARTIFICIAL INTELLIGENCE-DRIVEN INNOVATION IN ALZHEIMER'S THERAPEUTICS

P616 AI-Assisted Review Support Tool for Clinical Operations and Data Reconciliation in a Global Phase 3 Alzheimer's Disease Trial

Presenter: Phil Kang

Phil KANG, Lisa VADEN, Ja Yeon SHIN, Fred KIM, Jai Jun CHOUNG
AriBio Co., Ltd., San Diego, United-States

P79 Distinct Temporal Profiles of ARIA Subtypes During Donanemab Treatment: Real-World Experience from a Japanese Single-Center Cohort

Presenter: Taro Bannai

Taro BANNAI¹, Ryoko IHARA^{1,2}, Masanori KURIHARA^{1,2}, Ryosuke SHIMASAKI^{1,2,3}, Keiko HATANO¹, Fumio SUZUKI⁴, Aya MIDORI TOKUMARU⁴, Toshiaki AKASHI⁴, Kenji ISHII^{2,5}, Atsushi IWATA^{1,2}

¹ Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japon, ² Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japon, ³ Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japon, ⁴ Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japon, ⁵ Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japon

P128 Association of Ginseng Intake and Serum Zinc with Alzheimer's Disease-Related Cognition

Presenter: Shin Gyeom Kim

Young Min CHOE¹, Shin Gyeom KIM², Jee Wook KIM¹

¹ Hallim University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea, ² Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea

P180 Inflammatory Arthritis and Dementia

Presenter: Jun Hong Lee

Jun Hong LEE

National Health Insurance Service Ilsan Hospital, Goyang-Si, Republic of Korea

P688 From Diuresis to Dementia Prevention: How Carbonic Anhydrase Inhibitors May Modulate Dementia Risk in Glaucoma Patients

Presenter: Rachel Dolan

Rachel DOLAN¹, Reagan MCGINLEY², Estevao RIBEIRO³, Andrew MELSON⁴, Claire DELPIROU NOUH⁵

¹ University of Oklahoma College of Medicine, University of Oklahoma Health Campus, Oklahoma City, United-States, ² Baylor College of Medicine, Houston, United-States, ³ Department of Neurology, University of Oklahoma Health Campus - Oklahoma City United States, Oklahoma City, United-States, ⁴ Dean McGee Department of Ophthalmology, University of Oklahoma Health Campus, Oklahoma City, United-States, ⁵ Department of Neurology, University of Oklahoma Health Campus, Oklahoma City, United-States

PRE-CLINICAL, EARLY DISCOVERY AND MECHANISTIC RESEARCH

P7 Synergistic Effects of Mild Behavioral Impairment and APOE ϵ 4 on Cognitive Function in a Community-Based Middle-Aged and Older Population

Presenter: Cheng-Sheng Chen

Cheng-Sheng CHEN, Yi-Chun YEH, Hsiu-Fen LIN
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

P17 next-generation tau immunotherapy: NIDB-3101 biparatopic antibody PK, PD and tolerability data in NHP

Presenter: Jean-Philippe Courade

Jean-Philippe COURADE ¹, Nadia ANCERIZ ², Roman RÖSEMANN ³, Pauline LLOVERAS ², Laurence CHATEL ², Bruno DAUBEUF ², Alizée VIANDIER ², Adeline LESNIER ², Eric HATTERER ², Oleg DEMIN JR ⁴, Dmitry SHCHELOKOV ⁴, Galina SAYNUKOVA ⁴, Nicolas PRADEILLES ⁵, Sylvain LEHMANN ⁵
¹ discoveric bio alpha, Pfäffikon, Suisse, ² light chain biosciences, Plan Les Ouates, Suisse, ³ granzer, Muenchen, Germany, ⁴ Insysbio, Paphos, Chypre, ⁵ Laboratoire de Biochimie Protéomique Clinique CHU Montpellier, Montpellier, France

P45 How Re:Cognition Health (RCH) has Fast Tracked Patients to Receive Amyloid Targeted Treatment (ATT)

Presenter: Macsweney Emer

George ROBINSON ¹, Penny MUIR ², Macsweney EMER ¹
¹ Doctor, London, United Kingdom, ² EA, London, United Kingdom

P47 Polygenic risk score–based frailty index predicts conversion to tau-positivity in Alzheimer’s disease

Presenter: Mi-Young Oh

Mi-Young OH ¹, Sang-Hyuk JUNG ²
¹ Department of Neurology, Sejong General Hospital, Bucheon-Si, Republic of Korea, ² Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Republic of Korea

P188 Preclinical Validation of VGF-Derived Peptide TLQP-21 as an Intranasal Therapeutic in the 5xFAD Mouse Model of Alzheimer’s Disease

Presenter: Meenakshi Bose

Meenakshi BOSE ¹, Allen PAN ¹, Gabriela FARIAS-QUIPILDOR ^{2,3}, Yong HUANG ^{1,3}, Minghui WANG ⁴, Michelle EHRLICH ³, Stephen SALTON ¹
¹ Nash Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, United-States, ² Nash Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, New York, United-States, ³ Departments of Neurology, Genetics and Genomic Sciences, and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, United-States, ⁴ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United-States

P229 Preclinical Evaluation of CATA-002, a Novel A β /TfR Bispecific Brain-Shuttled Catalytic Antibody for Enhanced Brain Penetration and Enzymatic A β Degradation in Alzheimer’s Disease

Presenter: Yue Liu

Wang BO, Hoag MATTEW, Shan YUXI, Dong JIANBO, Fay NATHAN, Spadoni NICHOLAS, Putrevu SAROJA, Titong ALLISON, Yue LIU
Ab Studio Inc., Hayward, Ca, United-States

P263 QSP platform of Alzheimer’s Disease for exploring efficacy of anti-tau immunotherapy bepranemab

Presenter: Tatiana Karelina

Tatiana KARELINA, Dmitry GORDEEV, Olga IVANOVA, Polina MALIUKOVA
InSysBio, Paphos, Chypre

P299 HET3 mice are a model of brain aging: evidence for dendritic spine loss, proteome perturbations, and spatial learning deficits during aging.

Presenter: Josh Krivinko

Josh KRIVINKO ¹, Susan ERICKSON ¹, Akayla LEWIN ¹, Jiaqian LIU ², Matthew MACDONALD ¹, Jason NEWMAN ¹, Stacey RIZZO ³, Robert SWEET ^{1,4}

¹ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United-States, ² Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, United-States, ³ Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, United-States, ⁴ Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh

P334 Neural crest-derived nasal turbinate stem cells enhance the therapeutic efficacy of FDA-approved anti-A β immunotherapy in patient-derived Alzheimer's disease cerebral organoids

Presenter: Sung Won Kim

Jung Yeon LIM ¹, Jung Eun LEE ², Seung Ho YANG ², Hyun Kook LIM ³, Sung Won KIM ¹

¹ Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Republic of Korea, ² Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Republic of Korea, ³ Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Republic of Korea

P391 Binding profile of lecanemab in brain of patients with early Alzheimer's disease

Presenter: Linda Söderberg

Linda SÖDERBERG, Malin JOHANNESSON, Eleni GKANATSIU, Karolina MINTA, Olof ZACHRISSON, Gunilla OSSWALD, Lars LANNFELT, Christer MÖLLER

BioArctic AB, Stockholm, Suède

P457 Clearing Tau from the Inside Out: TRIM21-Mediated Immunotherapy Against Intracellular Tau Pathology

Presenter: Nemil Bhatt

Nemil BHATT, Nikita SHCHANKIN, Twisha CHATTERJEE, Jia Yi LIEW, Balci AHMET, Dhvani PANSURIYA, Rakez KAYED

University of Texas Medical Branch, Galveston, United-States

P660 Trends in Episodic Memory and Cognitive Symptoms in Cognitively Normal APOE2 Homozygotes

Presenter: Aimen Vanood

Aimen VANOOD, Meredith WICKLUND, Donna LOCKE, Blake LANGLAIS, Richard CASELLI, Bryan WOODRUFF

Mayo Clinic, Scottsdale, United-States

TRIAL DESIGN, STATISTICAL INNOVATION, AND ANALYTICAL FRAMEWORKS

P38 From Initial Enthusiasm to Routine Practice: Temporal Changes in Anti-Amyloid Therapy Uptake and Eligibility in Japan

Presenter: Ryoko Ihara

Ryoko IHARA, Masanori KURIHARA, Keiko HATANO, Taro BANNAI, Ryosuke SHIMASAKI, Akira HATAKEYAMA, Ko FURUTA, Fumio SUZUKI, Aya TOKUMARU, Kenji ISHII, Atsushi IWATA

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P67 Clinical and operational determinants of amyloid-targeting therapies treatment initiation in early Alzheimer's Disease: A discrete choice experiment

Presenter: Elena Garcia Arcelay

Juan FORTEA ¹, Elena GARCIA ARCELAY ², Alberto VILLAREJO ³, Raquel SANCHEZ DEL VALLE ⁴, Neus CANAL ⁵, Monica SARMIENTO ⁵, Jorge MAURIÑO ², Guillermo GARCIA-RIBAS ⁶, Gustavo SAPOSNIK ⁷

¹ Sant Pau Memory Unit, IR SANT PAU, Hospital Universitario de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Espagne, ² Medical Department, Roche Farma, Madrid, Espagne, ³ Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Espagne, ⁴ Department of Neurology, Hospital Clinic, FRCB- IDIBAPS, Universidad de Barcelona, Barcelona, Espagne, ⁵ RWCS, IQVIA Information, Madrid, Espagne, ⁶ Department of Neurology, Hospital Universitario Ramón y Cajal, Madrid, Espagne, ⁷ Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Canada. Clinical Outcomes and Decision Neuroscience Unit, Li Ka Shing Institute, University of Toronto, Toronto, Canada

P81 The Effects of Benzgalantamine (ZUNVEYL®) on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in the Treatment of Mild to Moderate Alzheimer's Dementia. RESOLVE: a Phase IV Open-label Study

Presenter: Denis Kay

Michael MCFADDEN, Denis KAY, Carson HARROD, Pavel SVINTOZELSKIY, Andrew WAHLERT, Kurt GRADY

Alpha Cognition Inc., Grapevine, United-States

P121 Most Screening–Baseline MMSE Variability Is Individual Noise: Pooled Analysis of 17 Alzheimer's Trials

Presenter: David Miller

David MILLER ¹, Alan KOTT ², Xingmei WANG ³

¹ Signant Health, Philadelphia, United-States, ² Signant Health, Prague, Tchéquie, ³ Signant Health, Blue Bell, United-States

P139 Achieving Greater Generalizability in Alzheimer's Clinical Trials through a Multi-sector Committee

Presenter: Christopher Miller

Christine LEE ¹, Christopher MILLER ², Michelle BRUNO ³, Daphne DELGADO ², Sam DICKSON ⁴, Martine MEYER ⁵, Constantina MIZIS ⁶, Jonathan TOBIN ⁷, Charisse WINSTON ⁸, Michael WEINER ⁹

¹ ACHIEVE Expertise, United-States, ² UsAgainstAlzheimer's, United-States, ³ MB Insights, LLC, United-States, ⁴ Pentara Corporation, United-States, ⁵ The Janssen Pharmaceutical Companies of Johnson & Johnson, United-States, ⁶ Latino Alzheimer's and Memory Disorders Alliance, United-States, ⁷ Clinical Directors Network, United-States, ⁸ University of Southern California, United-States, ⁹ University of California, San Francisco, United-States

P241 From short-term data to long-term trajectories: Statistical modeling framework for predicting multidomain progression in Alzheimer's disease

Presenter: Ryoichi Hanazawa

Ryoichi HANAZAWA, Hiroyuki SATO, Shin WATANABE, Ryo KITABAYASHI, Akihiro HIRAKAWA

Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan

P309 Responsible Data Sharing at Scale: Building Tiered Open Science Infrastructure for ADRD Clinical Trials

Presenter: Richard Gallardo

Richard GALLARDO ¹, Christian NAVARRO ¹, Michael DONOHUE ¹, Oliver LANGFORD ¹, Brenda ARMENTA-COPCA ¹, Hongmei QIU ¹, Paul NEWHOUSE ², Paul AISEN ¹, Gustavo JIMENEZ-MAGGIORA ¹

¹ University of Southern California, San Diego, United-States, ² Vanderbilt University, Nashville, United-States

P420 IMPACT-AD LATAM: A Regional Training Program to Strengthen ADRD Clinical Trial Capacity in Latin America

Presenter: Ma. Florencia Clarens

Ma. Florencia CLARENS¹, Maria C. CARRILLO², Joshua D. GRILL³, Rema RAMAN⁴, Heather M. SNYDER², Lucia CRIVELLI¹, Jorge LLIBRE-GUERRA⁵

¹ Department of Cognitive Neurology, Fleni, Buenos Aires, Argentine, ² Division of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, United-States, ³ Institute for Memory Impairments and Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University of California, Irvine, United-States, ⁴ Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United-States, ⁵ Department of Neurology, Washington University in St. Louis, St Louis, United-States

P486 Advancing Alzheimer's Disease Clinical Trials Through the Critical Path for Alzheimer's Disease Consortium (CPAD)

Presenter: Diane Stephenson

Yashmin KARTEN¹, Nicholas HENSCHIED¹, Colleen JACOBSEN¹, Hartmuth KOLB², Klaus ROMERO¹, Gregory KLEIN³, Diane STEPHENSON¹

¹ Critical Path Institute, Tucson, United-States, ² Enigma Biomedical Group, Knoxville, United-States, ³ F. Hoffmann-La Roche Ltd., Basel, Suisse

P525 Age-Dependent Sensitivity of the MMSE for Detecting Amyloid-Confirmed Alzheimer's Disease

Presenter: Dorothy Macfarlane

Dorothy MACFARLANE, Hale HAILIE, Nolan HADLEY, Vera LUKAS, Poplyk SOPHIA, Namaky NAUDER

Adams Clinical, Watertown, United-States

P569 Design considerations of a phase II multi-site randomized controlled trial of Harmony Dementia Care: a sensory-based intervention for people with Alzheimer's disease and related dementias

Presenter: Elizabeth K. Rhodus

Elizabeth K. RHODUS¹, David S. GELDMACHER², Rema RAMAN³, Michael DONOHUE³, Laura HENLEY¹, Clarissa BENZARTI¹, April STAUFFER¹, Nancy WOLFF¹, Kennedy WALCOTT-GEORGE¹, Susan WESTNEAT¹, Carolyn BAUM⁴, Paul AISEN³

¹ University of Kentucky, Lexington, United-States, ² University of Alabama at Birmingham, Birmingham, United-States, ³ Alzheimer's Therapeutic Research Institute, San Diego, United-States, ⁴ Washington University in St. Louis, St. Louis, United-States

P592 Listening Before Recruiting: Community Listening Sessions to Improve Alzheimer's Research Engagement

Presenter: Sonia Simons

Marilyn WILSON¹, B. Joy SNIDER¹, David CARR¹, Maryanna MILANEZ², Emily DUGAN¹, Jordan KULAGE¹, Sonia SIMONS¹

¹ Washington University School of Medicine, St. Louis, United-States, ² Global Alzheimer's Platform Foundation, Inc., Chicago, United-States

COGNITIVE AND FUNCTIONAL OUTCOMES

P28 Real-World Effectiveness of Lecanemab in Japanese Patients with Alzheimer's Disease: A Single-Center Study

Presenter: Ryosuke Shimasaki

Ryosuke SHIMASAKI ^{1,2,3}, Ryoko IHARA ^{1,2}, Masanori KURIHARA ^{1,2}, Kenichiro SATO ^{1,2,4}, Taro BANNAI ¹, Keiko HATANO ¹, Fumio SUZUKI ⁵, Aya TOKUMARU ⁵, Kenji ISHII ^{6,2}, Sumito OGAWA ³, Atsushi IWATA ^{1,2}

¹ Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ² Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ³ Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴ Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan, ⁵ Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ⁶ Research Team of Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P34 Digital Cognitive Signatures of Biomarker-Defined Preclinical Alzheimer's Disease

Presenter: Casey Vanderlip

Casey VANDERLIP ^{1,2}, Karra HARRINGTON ², Paul MARUFF ², Pam VENTOLA ²

¹ UC Irvine, Irvine, United-States, ² Cogstate Ltd, Melbourne, Australia

P76 Treatment-Related Amyloid Clearance with Lecanemab at 1-year : Stage-Dependent Response in a Real-World Cohort

Presenter: Jee Hyang Jeong

Jee Hyang JEONG ¹, Geon Ha KIM ²

¹ Ewha Womans University Seoul Hospital, Seoul, Republic of Korea, ² Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea

P130 Comparison-Based Subjective Cognitive Decline Predicts Objective Cognition in APOE ϵ 4 Non-Carriers

Presenter: Jee Wook Kim

Hye Ji CHOI ¹, Shin Gyeom KIM ², Jee Wook KIM ¹

¹ Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea, ² Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea

P201 ADAS-Cog 11 vs 13 in early Alzheimer's disease: sensitivity to longitudinal change

Presenter: Daema Pina Delgado

Catarina CUNHA ¹, Matt WELCH ², Daema PINA DELGADO ², Zsolt TERNEI ³, Selam NEGASH ², Chris RANDOLPH ²

¹ Clario, part of Thermo Fisher Scientific, Coimbra, Portugal, ² Clario, part of Thermo Fisher Scientific, Philadelphia, United-States, ³ Clario, part of Thermo Fisher Scientific, Budapest, Hongrie

P248 Experience, Not Education, Drives Rater Performance on the Clinical Dementia Rating Scale

Presenter: Dorothee Schoemaker

Dorothee SCHOEMAKER, Danielle DIGREGORIO, Selam NEGASH, Cong LIU, Chris RANDOLPH

Clario, part of Thermo Fisher Scientific, United-States

P284 Understanding NPI-C Rating Errors in AD Psychosis Trials: A Multi-Study Analysis of Hallucination and Delusion Domain Flags

Presenter: Amanda Aedo

Amanda AEDO, Gila BARBATI, Andrei IACOB, Sayaka MACHIZAWA, Erica APPLEMAN

Signant Health, Coral Springs, United-States

P289 Comparative analysis of lexical and acoustic speech biomarkers in mild cognitive impairment due to Lewy bodies and Alzheimer's disease

Presenter: Min Seok Baek

Min Seok BAEK ^{1,2}, Sung-Woo KIM ¹, Han-Kyeol KIM ¹, Mark LIBERMAN ³, Sunghye CHO ⁴

¹ Department of Neurology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, ² Linguistic Data Consortium & Linguistics Department, University of Pennsylvania, Philadelphia, United-States, ³ Linguistic Data Consortium & Linguistics Department, University of Pennsylvania, Philadelphia, Republic of Korea, ⁴ Department of Communication Sciences and Disorders, University of Cincinnati, Cincinnati, Republic of Korea

P484 Advancing Personalized Outcome Assessment in Frontotemporal Dementia: A Standardized Goal Inventory for Goal Attainment Scaling (GAS) in Clinical Trials

Presenter: Chere Chapman

Gunes Sevinc¹, Chere Chapman², Kaitlin Casaletto³, Howie Rosen³, Kenneth Rockwood⁴

¹Ardea Outcomes - Vancouver Canada, ²Ardea Outcomes - Halifax Canada, ³University of California, San Francisco - San Francisco Canada, ⁴University of California, San Francisco - Halifax Canada

P579 Technical and Real-World Validation of the Digital Clock and Recall: A Scalable Cognitive Screener for Primary Care and Clinical Trial Enrichment

Presenter: Ali Jannati

Claudio TORO-SEREY¹, Karl THOMPSON¹, Daniel SCHULMAN¹, Olivia JACKS¹, Connor HIGGINS¹, Alvaro PASCUAL-LEONE^{1,2}, Ali JANNATI¹, Sean TOBYNE¹

¹Linus Health, Boston, United-States, ²Hebrew SeniorLife - Harvard Medical School, Boston, United-States

P582 A Digital Clock and Recall (DCR)-First Clinical Workflow Substantially Increases Dementia Case-Finding in Primary Care

Presenter: Ali Jannati

Ali JANNATI¹, Claudio TORO-SEREY¹, Connor HIGGINS¹, John SHOWALTER¹, David BATES¹, Alvaro PASCUAL-LEONE^{1,2}, Sean TOBYNE¹

¹Linus Health, Boston, United-States, ²Hebrew SeniorLife - Harvard Medical School

P641 Effects of regional tau accumulation on visual discrimination behaviors in clinically unimpaired older adults

Presenter: Dhruv Kapadia

Dhruv KAPADIA¹, Lucah GUERRA¹, Isha SAI¹, Tyler BONNEN², Anthony WAGNER¹, Elizabeth MORMINO¹, Alexandra TRELLE¹

¹Stanford University, Stanford, United-States, ²University of Pennsylvania, Philadelphia, United-States

P707 Switching from Oral Donepezil to a Twice-weekly Korean Transdermal Donepezil Patch in Dementia with Parkinson's Disease

Presenter: Mee Y. Park

Mee Y. PARK¹, Jean Seo AN²

¹Neurology, Yeungnam University Medical Center, Daegu, Republic of Korea, ²Biological Sciences, University of Illinois Chicago UIC, Chicago, IL, Chicago, United-States

DIGITAL ENDPOINTS, REMOTE MONITORING, AND CONNECTED HEALTH TOOLS

P192 Automated verbal fluency as a digital cognitive biomarker in progressive supranuclear palsy: a longitudinal study

Presenter: Charlie Weige Zhao

Jesse WANG¹, Ilkay POTTER², Charlie Weige ZHAO¹, Ram MISHRA², Kyurim KANG³, Tejas PAWAR², Rylee COLE², Ashkan VAZIRI², Alexander PANTELYAT³, Anne-Marie WILLS¹

¹ Mass General Brigham, Boston, United-States, ² Biosensics LLC, Newton, United-States, ³ Johns Hopkins University, Baltimore, United-States

P195 Longitudinal digital speech assessment in progressive supranuclear palsy

Presenter: Charlie Weige Zhao

Kyurim KANG¹, Ilkay POTTER², Ram MISHRA², Rylee COLE², Tejas PAWAR², Charlie Weige ZHAO³, Antje MEFFERD⁴, Michael DE RIESTHAL⁵, Ashkan VAZIRI², Anne-Marie WILLS³, Alexander PANTELYAT³

¹ Johns Hopkins University, Baltimore, United-States, ² Biosensics LLC, Newton, United-States, ³ Mass General Brigham, Boston, United-States, ⁴ Vanderbilt University Medical Center, Nashville, United-States, ⁵ Vanderbilt University, Nashville, United-States

P211 Implementing the CMS GUIDE Dementia Care Model in a Community Neurology Practice with Digital Tools, Standardized Scales, Community Partners and Embedded Clinical Trial Recruitment

Presenter: Gregory Sahagian

Gregory SAHAGIAN

The Neurology Center of Southern California, Carlsbad, United-States

P281 Ensuring Demographic Equity: Evaluating the SB-C Speech-Based Cognitive Assessment Across Ethnic Groups in US

Presenter: Alexandra König

Johannes TRÖGER, Louisa SCHWED, Simona SCHÄFER, Alison BUICK, Nicklas LINZ, Alexandra KÖNIG

ki elements GmbH, Saarbrücken, Germany

P400 Improving Early Detection of Cognitive Impairment with Cognivue Clarity Across Diverse Clinical Settings: Accounting for Age, Education and Race Differences in Performance

Presenter: James Galvin

James GALVIN¹, Paul ESTES², Heather HARRIS², Lun-Ching CHANG³

¹ University of Miami Miller School of Medicine, Boca Raton, United-States, ² Cognivue, Inc, Victor, United-States, ³ Florida Atlantic University, Boca Raton, United-States

P401 Remote Odor Percept Identification as a Scalable Marker of Alzheimer's Disease

Presenter: Benoît Jobin

Benoît JOBIN, Colin MAGDAMO, Hengbin ZHANG, Beyzanur ERGUN, Sean REINEKE, Alefiya DHILLA-ALBERS, Mark ALBERS

Mass General Brigham/Harvard Medical School, Boston, United-States

P470 Evaluation of the Effects of Donepezil on Cognition and Daily Function in Amyloid-Positive MCI: An Exploratory Randomized Study Using Eye-Tracking Metrics

Presenter: Ko Woon Kim

Ko Woon KIM^{1,2}, Byung-Soo SHIN^{1,3}

¹ Department of Neurology, Jeonbuk National University Medical School and Hospital, Jeonju, Republic of Korea, ² Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Corée République populaire démocratique de, ³ Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea

NEW HYPOTHESES – NEW THERAPEUTIC APPROACHES FOR AD

P15 Pipeline Diversification and Emerging Therapeutic Hypotheses in Alzheimer's Disease

Presenter: Laurentiu Gutiu

Laurentiu GUTIU ¹, Abby FULLER ², Antoniya TODOROVA ³

¹ Fortrea Germany GmbH, Munich, Germany, ² Fortrea Inc., Durham, United-States, ³ Fortrea Belgium SRL, Brussels, Belgium

P42 Multidimensional Evaluation of Deep Cervical Lymphatic-Venous Anastomosis and Lymphatic stemnectomy in Alzheimer's Disease: A 12-Month Single-arm Prospective Study

Presenter: Yan Chen

Yan CHEN ¹, Chenpeng ZHANG ², Jing WANG ³, Yang YANG ¹, Qianqian GUO ¹, Ziyi LIU ¹, Chuantao ZUO ³, Ren ZHENGHU ⁴, Xia LI ¹

¹ Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ² Department of Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ³ Department of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China, ⁴ Department of Oral and Maxillofacial & Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China

P141 Treatment of age-related upstream bioenergetic and redox impairment promotes clearance of A β and tau aggregates, lowers oxidative nitration and promotes synapse formation in isolated neurons from AD mouse models

Presenter: Gregory Brewer

Gregory BREWER ¹, Svara SHAH ¹, Ricardo SANTANA ²

¹ UC Irvine, Irvine, United-States, ² UNAM, Mexico City, Mexico

P159 Is cerebral A β 42-amyloidosis (CAB42-A) a more appropriate labelling for asymptomatic patients than Alzheimer's disease?

Presenter: Michaela Defrancesco

Michaela DEFRADESCO

Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria, Innsbruck, Austria

P501 Phase 1 Clinical Development Strategy for PNA5 in VCID: Translational Biomarkers, Neurovascular Mechanisms, and SAD/MAD Design

Presenter: Meredith Hay

Meredith HAY, Tamara CROCKETT

ProNeurogen, Inc, Tucson, United-States

P524 Feasibility of a multidomain intervention combining Reduced carbohydrate intake, Omega-3 fatty acids, MCT supplementation, and EXercise in older adults at risk of Alzheimer's disease: the ROMEX-AD trial.

Presenter: Melanie Fortier

Melanie FORTIER ¹, Christian BOCTI ¹, Mark ESPELAND ², Matthew PHILLIPS ³, Stephen CUNNANE ¹

¹ Research Center on Aging and Department of Medicine, Université de Sherbrooke, Sherbrooke, Canada, ² Wake Forest University School of Medicine, Winston-Salem, United-States, ³ Research Center on Aging and Department of Medicine, Université de Sherbrooke, Hamilton, New Zealand